AMGEN PRESENTS NEW PHASE 2 DATA THAT SHOW OLPASIRAN DELIVERS SIGNIFICANT REDUCTION IN LIPOPROTEIN(A) LEVELS ...Middle East

PR Newswire - News
AMGEN PRESENTS NEW PHASE 2 DATA THAT SHOW OLPASIRAN DELIVERS SIGNIFICANT REDUCTION IN LIPOPROTEIN(A) LEVELS
Olpasiran Reduced Lipoprotein(a) Levels by More Than 95% in Patients With Established ASCVD Amgen is Initiating a Phase 3 Cardiovascular Outcomes Trial Based on These Results Data Simultaneously Published in the New England Journal of Medicine THOUSAND OAKS, Calif. , Nov. 6, 2022...

Hence then, the article about amgen presents new phase 2 data that show olpasiran delivers significant reduction in lipoprotein a levels was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AMGEN PRESENTS NEW PHASE 2 DATA THAT SHOW OLPASIRAN DELIVERS SIGNIFICANT REDUCTION IN LIPOPROTEIN(A) LEVELS )

Apple Storegoogle play

Last updated :

Also on site :



Latest News
before 17 minute